The European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union’s first PD-(L)1 cancer immunotherapy for subcutaneous injection. Roche announced that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union’s first PD-(L)1…
AbbVie announced the launch of PRODUODOPA® in the EU for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia, and when available combinations of Parkinson’s medicinal products have not given satisfactory results. PRODUODOPA is the first-and-only…
Merck, known as MSD outside of the United States and Canada, and Harpoon Therapeutics today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash…
Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its marketing authorization application for the next-generation tyrosine kinase inhibitor (TKI) repotrectinib as a treatment for ROS1 TKI-naïve and -pretreated adult patients with ROS1-positive locally advanced or metastatic…
AstraZeneca and Ionis Pharmaceuticals, Inc.’s Wainua (eplontersen) has been approved in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. Wainua is the only approved medicine for the…
Doctors from the Department of Plastic Surgery and Hand Surgery at the Universitätsspital Zürich created a new drain to relieve the patient’s agonizing lymph congestion. For the first time, a microsurgical operating system was used for such a procedure. By…
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced today that FDA approved FILSUVEZ® (birch triterpenes) topical gel for the treatment of partial thickness…
Merck, known as MSD outside of the United States and Canada, announced the European Commission (EC) has approved two new indications for KEYTRUDA, Merck’s anti-PD-1 therapy, in gastrointestinal cancers: 👉 KEYTRUDA in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the…
Merck known as MSD outside of the United States and Canada, announced that FDA has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death…
Merck Healthcare, a leading science and technology company, and the Pediatric Praziquantel Consortium today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for arpraziquantel for the…